Summary This metadata record provides details of the data supporting the claims of the related manuscript: “Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer:

NIAID Data Ecosystem60

Selective inhibition of SIN3 corepressor with avermectins as a novel therapeutic strategy in triple negative breast cancer. Homo sapiens

三阴性乳腺癌治疗

药物作用机制

Triple negative breast cancers (TNBC) lacking estrogen, progesterone and HER2 receptors account for 10-20% of breast cancer and are indicative of poor prognosis. The development of effective treatment

NIAID Data Ecosystem40

Conjugates Derived from Lapatinib Derivatives with Cancer Cell Stemness Inhibitors Effectively Reversed Drug Resistance in Triple-Negative Breast Cancer

三阴性乳腺癌治疗

多药耐药逆转

Increasing evidence indicates that the cancer stem cell (CSC) subpopulation contributes to the therapeutic resistance and metastasis of tumors, leading to patient recurrence and death. Herein, we desi

NIAID Data Ecosystem60

Cytochalasin D as a potential MAPK family inhibitor for treating triple-negative breast cancer

三阴性乳腺癌治疗

MAPK信号通路

Cytochalasin D, a potent fungal metabolite, has garnered considerable attention due to its diverse biological activities and potential pharmacological applications. Renowned for its ability to disrupt

Taylor & Francis Group2025-02-27 更新50

Table 2 from Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer

资源简介：

相关数据集